Skip to main content

Table 1 Clinico-pathological data of case and control subjects. (A) Tissue samples and (B) Plasma samples used for the study

From: Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma

Subjects Total number Number of males Number of females Mean age (Years) Age range (years)
(A) Tissue samples
Total GBC Cases 7 0 7 50.86 30–66
Stages
 GBC, Stage I 1 0 1 38 38
 GBC, Stage II 1 0 1 65 65
 GBC, Stage IIIA 5 0 5 50.6 30–66
Histological grade
 Well-differentiated (G1) 1 0 1
 Moderately-differentiated (G2) 4 0 4
 Poorly-differentiated (G3) 2 0 2
(B) Plasma samples
Total GBC Cases 52 10 42 50.88 22–78
Stages
 GBC, Stage I 6 1 5 39.66 22–47
 GBC, Stage II 6 1 5 52.16 34–66
 GBC, Stage III 17 2 15 52.76 30–66
 GBC, Stage IV 23 6 17 52.08 38–78
 Early Stages (I and II) 12 2 10 45.91 22–66
 Advanced stages (III and IV) 40 8 32 52.37 30–78
LN status
 LN negative 23 2 21 48.91 22–66
 LN positive 29 8 21 52.44 38–78
Histological grade
 Well-differentiated (G1) 5 0 5
 Moderately-differentiated (G2) 32 5 27
 Poorly-differentiated (G3) 15 2 13
Total Controls 89 28 61 40.89 20–72
GSD cases 48 13 35 43.06 20–72
Healthy group 41 15 26 38.36 24–59
  1. GBC Gallbladder carcinomas, GSD Gallstone disease, LN Lymph node
\